Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

Pomalidomide + low-dose dexamethasone is effective and well tolerated for refractory or relapsed and refractory multiple myeloma after bortezomib and lenalidomide failure. The phase III trial MM-003 compared pomalidomide + low-dose dexamethasone with high-dose dexamethasone. This subanalysis grouped...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Haematologica
Asıl Yazarlar: Weisel, Katja C., Dimopoulos, Meletios A., Moreau, Philippe, Lacy, Martha Q., Song, Kevin W., Delforge, Michel, Karlin, Lionel, Goldschmidt, Hartmut, Banos, Anne, Oriol, Albert, Alegre, Adrian, Chen, Christine, Cavo, Michele, Garderet, Laurent, Ivanova, Valentina, Martinez-Lopez, Joaquin, Knop, Stefan, Yu, Xin, Hong, Kevin, Sternas, Lars, Jacques, Christian, Zaki, Mohamed H., Miguel, Jesus San
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2016
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5004467/
https://ncbi.nlm.nih.gov/pubmed/27081177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.137083
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller